<SEC-DOCUMENT>0001193125-19-019701.txt : 20190129
<SEC-HEADER>0001193125-19-019701.hdr.sgml : 20190129
<ACCEPTANCE-DATETIME>20190129073106
ACCESSION NUMBER:		0001193125-19-019701
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		4
CONFORMED PERIOD OF REPORT:	20190128
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20190129
DATE AS OF CHANGE:		20190129

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			NEUROCRINE BIOSCIENCES INC
		CENTRAL INDEX KEY:			0000914475
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				330525145
		STATE OF INCORPORATION:			CA
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-22705
		FILM NUMBER:		19547129

	BUSINESS ADDRESS:	
		STREET 1:		12780 EL CAMINO REAL
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92130
		BUSINESS PHONE:		(858) 617-7600

	MAIL ADDRESS:	
		STREET 1:		12780 EL CAMINO REAL
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92130
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d665990d8k.htm
<DESCRIPTION>8-K
<TEXT>
<HTML><HEAD>
<TITLE>8-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>FORM <FONT
STYLE="white-space:nowrap">8-K</FONT> </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>CURRENT
REPORT </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to Section&nbsp;13 or 15(d) of the </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Securities Exchange Act of 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Date of Report (Date of earliest event reported): January&nbsp;28, 2019 </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>NEUROCRINE BIOSCIENCES, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Exact name of registrant as specified in its charter) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B>Delaware</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B><FONT STYLE="white-space:nowrap">0-22705</FONT></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B><FONT STYLE="white-space:nowrap">33-0525145</FONT></B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(State or other jurisdiction of</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>incorporation)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Commission</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>File Number)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(IRS Employer</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Identification No.)</B></P></TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="50%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B>12780 El Camino Real, San Diego, California</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>92130</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"><B>(Address of principal executive offices)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>(Zip Code)</B></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Registrant&#146;s telephone number, including area code: (858)
<FONT STYLE="white-space:nowrap">617-7600</FONT> </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>N/A </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Former name or former address, if changed since last report.) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box below if the Form <FONT STYLE="white-space:nowrap">8-K</FONT> filing is intended to simultaneously satisfy the filing obligation of
the registrant under any of the following provisions: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Soliciting material pursuant to Rule <FONT STYLE="white-space:nowrap">14a-12</FONT> under the Exchange Act (17
CFR <FONT STYLE="white-space:nowrap">240.14a-12)</FONT> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><FONT STYLE="white-space:nowrap">Pre-commencement</FONT> communications pursuant to Rule <FONT
STYLE="white-space:nowrap">14d-2(b)</FONT> under the Exchange Act (17 CFR <FONT STYLE="white-space:nowrap">240.14d-2</FONT> (b)) </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><FONT STYLE="white-space:nowrap">Pre-commencement</FONT> communications pursuant to Rule <FONT
STYLE="white-space:nowrap">13e-4(c)</FONT> under the Exchange Act (17 CFR <FONT STYLE="white-space:nowrap">240.13e-4</FONT> (c)) </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933
(&#167;230.405 of this chapter) or Rule <FONT STYLE="white-space:nowrap">12b-2</FONT> of the Securities Exchange Act of 1934 <FONT STYLE="white-space:nowrap">(&#167;240.12b-2</FONT> of this chapter). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Emerging growth company&nbsp;&nbsp;&#9744; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&nbsp;13(a) of the Exchange
Act.&nbsp;&nbsp;&#9744; </P> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Item&nbsp;1.01 Entry into a Material Definitive Agreement. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Collaboration and License Agreement </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On January&nbsp;28,
2019 (the &#147;<B><I>Agreement Date</I></B>&#148;), Neurocrine Biosciences, Inc. (the &#147;<B><I>Company</I></B>&#148;) entered into a Collaboration and License Agreement (the &#147;<B><I>Collaboration Agreement</I></B>&#148;) with Voyager
Therapeutics, Inc. (&#147;<B><I>Voyager</I></B>&#148;) for the research, development and commercialization of adeno-associated virus (&#147;<B><I>AAV</I></B>&#148;)-based gene therapy products. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Collaboration and Licenses</I>. Under the Collaboration Agreement, upon the expiration or termination of applicable waiting periods and the receipt of any
required approvals or clearances under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (such date, the &#147;<B><I>Effective Date</I></B>&#148; and such clearance, &#147;<B><I>Antitrust Clearance</I></B>&#148;), the Company and
Voyager have agreed to collaborate on the conduct of four collaboration programs (the &#147;<B><I>Programs</I></B>&#148;): Voyager&#146;s <FONT STYLE="white-space:nowrap">VY-AADC</FONT> program, intended to advance Voyager&#146;s <FONT
STYLE="white-space:nowrap">VY-AADC</FONT> product candidate for the treatment of Parkinson&#146;s disease, which is currently in an ongoing Phase 2 trial (the &#147;<B><I>AADC Program</I></B>&#148;); Voyager&#146;s program intended to generate gene
therapy product candidates for the treatment of Friedreich&#146;s ataxia, including Voyager&#146;s <FONT STYLE="white-space:nowrap">VY-FXN01</FONT> product candidate (the &#147;<B><I>FA Program</I></B>&#148; and, collectively with the AADC Program,
the &#147;<B><I>Existing Programs</I></B>&#148;); and two programs to be determined by the Company and Voyager at a later date, as described below (each a &#147;<B><I>Discovery Program</I></B>&#148; and, collectively, the &#147;<B><I>Discovery
Programs</I></B>&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the terms of the Collaboration Agreement, subject to the rights retained by Voyager thereunder, Voyager has agreed to
collaborate with the Company on, and to grant, as of the Effective Date, exclusive, royalty-bearing, <FONT STYLE="white-space:nowrap">non-transferable,</FONT> sublicensable licenses to certain of Voyager&#146;s intellectual property rights, for all
human and veterinary diagnostic, prophylactic, and therapeutic uses, for the research, development, and commercialization of gene therapy products (the &#147;<B><I>Collaboration Products</I></B>&#148;) under (i)&nbsp;the AADC Program, on a worldwide
basis; (ii)&nbsp;the FA program, for the United States and, upon expiration of Sanofi Genzyme&#146;s option to the FA Program pursuant to its ongoing collaboration with Voyager (the &#147;<B><I>Sanofi Genzyme Collaboration</I></B>&#148;) without
exercise of such option, all countries in the world in which the Collaboration Agreement remained in effect with respect to the FA Program; and (iii)&nbsp;each Discovery Program, on a worldwide basis. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to development plans agreed to by the Company and Voyager, and as overseen by a joint steering committee (&#147;<B><I>JSC</I></B>&#148;), Voyager has
operational responsibility, subject to certain exceptions, for the conduct of each Program (prior to the Transition Event (as defined below) for each Program) and is required to use commercially reasonable efforts to develop the Collaboration
Products. The Company has agreed to be responsible for all costs incurred by Voyager in conducting these activities for each Program, in accordance with an agreed budget. If Voyager breaches its development responsibilities or in certain
circumstances upon a change in control of Voyager, the Company has the right but not the obligation to assume the activities under such Program. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Upon the
occurrence of a specified event for each Program (a &#147;<B><I>Transition Event</I></B>&#148;), the Company agrees to assume responsibility for development, manufacturing and commercialization activities for such Program from Voyager and to pay
milestones and royalties on future net sales as described further below. For each Existing Program, Voyager has the option (a &#147;<B><I><FONT STYLE="white-space:nowrap">Co-Co</FONT> Option</I></B>&#148;) to
<FONT STYLE="white-space:nowrap">co-develop</FONT> and <FONT STYLE="white-space:nowrap">co-commercialize</FONT> such Program upon the occurrence of a specified event (a &#147;<B><I><FONT STYLE="white-space:nowrap">Co-Co</FONT> Trigger
Event</I></B>&#148;). Should Voyager elect to exercise its <FONT STYLE="white-space:nowrap">Co-Co</FONT> Option, the Company and Voyager agree to enter into a cost- and profit-sharing arrangement (a
&#147;<B><I><FONT STYLE="white-space:nowrap">Co-Co</FONT> Agreement</I></B>&#148;) whereby the Company and Voyager agree to jointly develop and commercialize Collaboration Products for such Program
(&#147;<B><I><FONT STYLE="white-space:nowrap">Co-Co</FONT> Products</I></B>&#148;) and share in its costs, profits and losses, and Voyager agrees to forfeit certain milestones and royalties on net sales in the United States during the effective
period of the applicable <FONT STYLE="white-space:nowrap">Co-Co</FONT> Agreement. The Transition Events are (i)&nbsp;with respect to the AADC Program, Voyager&#146;s receipt of topline data for the ongoing Phase 2 clinical trial for <FONT
STYLE="white-space:nowrap">VY-AADC;</FONT> (ii)&nbsp;with respect to the FA Program, Voyager&#146;s receipt of topline data for the initial Phase 1 clinical trial for an FA Program product candidate; and (iii)&nbsp;with respect to each Discovery
Program, the preparation by Voyager and the approval by the Company of an investigational new drug application to be filed with the U.S. Food and Drug Administration (&#147;<B><I>FDA</I></B>&#148;) by the Company for the first development candidate
in such Discovery Program. The <FONT STYLE="white-space:nowrap">Co-Co</FONT> Trigger Events are (i)&nbsp;with respect to the AADC Program, Voyager&#146;s receipt of topline data for the ongoing Phase 2 clinical trial for <FONT
STYLE="white-space:nowrap">VY-AADC</FONT> and (ii)&nbsp;with respect to the FA Program, the achievement of milestones or metrics specified in the applicable development plan, as determined by the JSC. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Subject to exceptions specified in the Collaboration Agreement, profits and losses under Voyager&#146;s <FONT STYLE="white-space:nowrap">Co-Co</FONT> Option
are agreed to be allocated (i)&nbsp;50% to the Company and 50% to Voyager for a Collaboration Product from the AADC Program and (ii)&nbsp;60% to the Company and 40% to Voyager for a Collaboration Product from the FA Program; provided, however, that
the Company may elect, within a specified period following the acceptance for filing of a biologics license application from the FDA, to pay a $35&nbsp;million rate-shifting fee to Voyager to change the allocation for the AADC Program to 55% to the
Company and 45% to Voyager. The parties have agreed that each <FONT STYLE="white-space:nowrap">Co-Co</FONT> Agreement will provide Voyager the right to terminate for any reason upon prior written notice to the Company, and the Company the right to
terminate in certain circumstances upon a change of control of Voyager. </P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Candidate Selection</I>. The Company and Voyager have committed, following the Effective Date, to agree
on a list of up to eight target genes (&#147;<B><I>Targets</I></B>&#148;), from which the Company has the right to nominate Targets for the two Discovery Programs. Each Target for the Discovery Programs must be approved by a consensus of the JSC or
the executive officers of the parties. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Financial Terms</I>. Under the terms of the Collaboration Agreement, the Company has agreed to pay Voyager an
upfront payment of $115&nbsp;million (the &#147;<B><I>Upfront Payment</I></B>&#148;) within five business days after the Effective Date. The Collaboration Agreement provides for aggregate development milestone payments from the Company to Voyager
for Collaboration Products under (i)&nbsp;the AADC Program of up to $170&nbsp;million; (ii)&nbsp;the FA Program of up to $195&nbsp;million, and (iii)&nbsp;each of the two Discovery Programs of up to $130&nbsp;million per Discovery Program. Voyager
may be entitled to receive aggregate commercial milestone payments for each Collaboration Product of up to $275&nbsp;million, subject to an aggregate cap on commercial milestones across all Programs of $1.1&nbsp;billion. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company has also agreed to pay Voyager royalties, based on future net sales of the Collaboration Products. Such royalty percentages, for net sales in and
outside the United States, range from (i)&nbsp;for the AADC Program, the <FONT STYLE="white-space:nowrap">mid-teens</FONT> to thirty and the <FONT STYLE="white-space:nowrap">low-teens</FONT> to twenty, respectively; (ii)&nbsp;for the FA Program, <FONT
STYLE="white-space:nowrap">low-teens</FONT> to high-teens and high-single digits to <FONT STYLE="white-space:nowrap">mid-teens,</FONT> respectively; and (iii)&nbsp;for each Discovery Program, high-single digits to
<FONT STYLE="white-space:nowrap">mid-teens</FONT> and <FONT STYLE="white-space:nowrap">mid-single</FONT> digits to <FONT STYLE="white-space:nowrap">low-teens,</FONT> respectively. On a
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">country-by-country</FONT></FONT> and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Program-by-Program</FONT></FONT> basis, royalty payments would commence on the
first commercial sale of a Collaboration Product and terminate on the later of (a)&nbsp;the expiration of the last patent covering the Collaboration Product or its method of use in such country, (b) 10 years from the first commercial sale of the
Collaboration Product in such country and (c)&nbsp;the expiration of regulatory exclusivity in such country (the &#147;<B><I>Royalty Term</I></B>&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Termination</I>.&nbsp;Unless earlier terminated, the Collaboration Agreement expires on the later of (i)&nbsp;the expiration of the last to expire Royalty
Term with respect to a Collaboration Product in all countries in the relevant territory or (ii)&nbsp;the expiration or termination of all <FONT STYLE="white-space:nowrap">Co-Co</FONT> Agreements. The Company may terminate the Collaboration Agreement
in its entirety or on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Program-by-Program</FONT></FONT> or <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">country-by-country</FONT></FONT> basis by providing at
least (x) <FONT STYLE="white-space:nowrap">180-day</FONT> advance notice if such notice is provided prior to the first commercial sale of the Collaboration Product to which the termination applies or
<FONT STYLE="white-space:nowrap">(y)&nbsp;one-year</FONT> advance notice if such notice is provided after the first commercial sale of the Collaboration Product to which the termination applies. Voyager may terminate the Collaboration Agreement,
subject to specified conditions, if (i)&nbsp;the Company fails to make the equity purchase described in greater detail below or (ii)&nbsp;the Company challenges the validity or enforceability of certain Voyager intellectual property rights. Subject
to a cure period, either party may terminate the Collaboration Agreement in the event of a material breach in whole or in part, subject to specified conditions.&nbsp;Either party may also terminate the Collaboration Agreement if specified regulatory
agencies seek to enjoin the transaction or if the parties are unable to obtain Antitrust Clearance within 180 days of the Agreement Date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The foregoing
description of the terms of the Collaboration Agreement does not purport to be complete and is qualified in its entirety by reference to the full text of the Collaboration Agreement, a copy of which will be filed with the Securities and Exchange
Commission as an exhibit to the Company&#146;s Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the year ended December&nbsp;31, 2018. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Stock Purchase Agreement </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with the
execution of the Collaboration Agreement, the Company and Voyager also entered into a stock purchase agreement on the Agreement Date (the &#147;<B><I>Stock Purchase Agreement</I></B>&#148;) for the sale and issuance of 4,179,728 shares of common
stock (the &#147;<B><I>Shares</I></B>&#148;) to the Company at a price of $11.9625 per share, for an aggregate purchase price of approximately $50.0&nbsp;million. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The consummation of the transactions contemplated by the Stock Purchase Agreement is subject to the parties&#146; obtaining Antitrust Clearance, the
Collaboration Agreement and Investor Agreement (as defined below) remaining in full force and effect, and the satisfaction or waiver of other customary closing conditions. The parties have agreed to hold the closing of the purchase and sale of the
Shares (the &#147;<B><I>Closing</I></B>&#148;) on the second business day after the satisfaction or waiver of such closing conditions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Stock Purchase
Agreement may be terminated upon the mutual consent of the parties. Either party may terminate the Stock Purchase Agreement upon written notice to the other party if certain closing conditions are unable to be met within 180 days of applicable
antitrust filings. Subject to specified exceptions, either party also may terminate the Stock Purchase Agreement prior to the Closing upon material breach of certain covenants or agreements by the other party or upon certain representations and
warranties of such other party becoming untrue. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The foregoing description of the terms of the Stock Purchase Agreement does not purport to be complete
and is qualified in its entirety by reference to the full text of the Stock Purchase Agreement, a copy of which will be filed with the Securities and Exchange Commission as an exhibit to the Company&#146;s Annual Report on Form <FONT
STYLE="white-space:nowrap">10-K</FONT> for the year ended December&nbsp;31, 2018. </P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Investor Agreement </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with the execution of the Collaboration Agreement, the Company and Voyager also entered into an investor agreement on the Agreement Date (the
&#147;<B><I>Investor Agreement</I></B>&#148;) providing for standstill and <FONT STYLE="white-space:nowrap">lock-up</FONT> restrictions and a voting agreement with respect to the Shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the terms of the Investor Agreement, the Company has agreed not to, without the prior written approval of Voyager and subject to specified
conditions, directly or indirectly acquire shares of Voyager&#146;s outstanding common stock, seek or propose a tender or exchange offer or merger between the parties, solicit proxies or consents with respect to any matter, or undertake other
specified actions related to the potential acquisition of additional equity interests in Voyager (the &#147;<B><I>Standstill Restrictions</I></B>&#148;). Further, the Company has also agreed not to, and to cause its affiliates not to, sell or
transfer the Shares without the prior written approval of Voyager, subject to specified conditions (the &#147;<B><I><FONT STYLE="white-space:nowrap">Lock-Up</FONT> Restrictions</I></B>&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, pursuant to the terms of the Investor Agreement, the Company has agreed that the Shares are subject to a voting agreement such that, subject to
specified conditions and excluding specified extraordinary matters, the Company has agreed to, and has agreed to cause its permitted transferees to, vote in accordance with the recommendation of Voyager&#146;s Board of Directors and has granted
Voyager an irrevocable proxy with respect to the foregoing (the &#147;<B><I>Voting Agreement</I></B>&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Each of the Standstill Restrictions, the <FONT
STYLE="white-space:nowrap">Lock-Up</FONT> Restrictions, and the Voting Agreement terminate upon the earliest to occur of (i)&nbsp;a liquidation or dissolution of Voyager, and (ii)&nbsp;the later of the third anniversary of the date of the Closing
and the initial announcement or release of topline results from Voyager&#146;s anticipated second pivotal clinical trial. The Standstill Restrictions and Voting Agreement also terminate upon the expiration or termination of the Collaboration
Agreement, if earlier. The Standstill Restrictions and <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Restrictions also terminate upon the deregistration of Voyager&#146;s common stock, if earlier. The
<FONT STYLE="white-space:nowrap">Lock-Up</FONT> Restrictions and Voting Agreement also terminate on a change in control of Voyager or the date on which the Company and its affiliates beneficially own less than three percent of the common stock of
Voyager on an outstanding basis. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The foregoing description of the terms of the Investor Agreement does not purport to be complete and is qualified in its
entirety by reference to the full text of the Investor Agreement, a copy of which will be filed with the Securities and Exchange Commission as an exhibit to the Company&#146;s Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for
the year ended December&nbsp;31, 2018. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Forward-Looking Statements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This Current Report on Form <FONT STYLE="white-space:nowrap">8-K</FONT> contains &#147;forward-looking statements&#148; within the meaning of Section&nbsp;27A
of the Securities Act of 1933, as amended, and Section&nbsp;21E of the Securities Exchange Act of 1934, as amended. These statements relate to future events and involve known and unknown risks, uncertainties and other factors which may cause the
Company&#146;s actual results, performance or achievements to be materially different from any future results, performances or achievements expressed or implied by the forward-looking statements. In some cases, you can identify forward-looking
statements by terms such as &#147;may&#148;, &#147;will&#148;, &#147;should&#148;, &#147;could&#148;, &#147;would&#148;, &#147;expects&#148;, &#147;plans&#148;, &#147;anticipates&#148;, &#147;believes&#148;, &#147;estimates&#148;,
&#147;projects&#148;, &#147;predicts&#148;, &#147;potential&#148; and similar expressions intended to identify forward-looking statements. These statements reflect the Company&#146;s current views with respect to future events and are based on
assumptions and subject to risks and uncertainties. Given these uncertainties, you should not place undue reliance on these forward-looking statements. Also, these forward-looking statements represent the Company&#146;s estimates and assumptions
only as of the date of this Current Report on Form <FONT STYLE="white-space:nowrap">8-K.</FONT> </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Item&nbsp;9.01 Financial Statements and Exhibits
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(d) Exhibits </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">99.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><A HREF="d665990dex991.htm">Joint Press Release of Neurocrine Biosciences, Inc. and Voyager Therapeutics, Inc. dated
 January&nbsp;29, 2019. </A> </P></TD></TR></TABLE>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="47%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="46%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Dated: January&nbsp;29, 2019</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">NEUROCRINE BIOSCIENCES, INC.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Darin M. Lippoldt</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Darin M. Lippoldt</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Chief Legal Officer</TD></TR>
</TABLE>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d665990dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="51%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:1pt">


<IMG SRC="g665990g69f98.jpg" ALT="LOGO">
</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">


<IMG SRC="g665990g21s30.jpg" ALT="LOGO">
</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Neurocrine Biosciences and Voyager Therapeutics Form Strategic Development and Commercialization
Collaboration for Parkinson&#146;s Disease and Friedreich&#146;s Ataxia </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>Collaboration leverages strengths and efforts of both
companies towards developing and commercializing life-changing treatments for severe neurological diseases </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>Neurocrine Biosciences
gains development and commercialization rights to gene therapy programs <FONT STYLE="white-space:nowrap">VY-AADC</FONT> for Parkinson&#146;s disease, <FONT STYLE="white-space:nowrap">VY-FXN01</FONT> for Friedreich&#146;s ataxia and two additional
programs to be determined </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>Voyager receives $165&nbsp;million upfront, along with funding for ongoing development of each program,
and up to $1.7&nbsp;billion in potential development, regulatory and commercial milestone payments </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>SAN DIEGO, and CAMBRIDGE, Mass., Jan. 29,
2019</B> &#150; Neurocrine Biosciences, Inc. (NASDAQ: NBIX) and Voyager Therapeutics, Inc. (NASDAQ: VYGR), today announced the formation of a strategic collaboration focused on the development and commercialization of Voyager&#146;s gene therapy
programs, <FONT STYLE="white-space:nowrap">VY-AADC</FONT> for Parkinson&#146;s disease and <FONT STYLE="white-space:nowrap">VY-FXN01</FONT> for Friedreich&#146;s ataxia, as well as rights to two programs to be determined. This collaboration combines
Neurocrine Biosciences&#146; expertise in neuroscience, drug development and commercialization with Voyager&#146;s innovative gene therapy programs targeting severe neurological diseases. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Neurocrine Biosciences and Voyager will each host a company conference call and webcast to discuss the collaboration. Full webcast details are provided below.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;We are excited to collaborate with Voyager to advance our shared mission to discover and develop medicines that can benefit the lives of people
with serious neurological disorders,&#148; said Kevin Gorman, Ph.D., chief executive officer of Neurocrine Biosciences. &#147;The partnership with Voyager allows us to expand our clinical development pipeline addressing neurological disorders,
leverage Voyager&#146;s expertise in <FONT STYLE="white-space:nowrap">CNS-focused</FONT> gene therapy, and develop potential treatments for diseases, such as Parkinson&#146;s disease and Friedreich&#146;s ataxia, which have significant unmet
clinical needs.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;Neurocrine Biosciences is an ideal partner with its proven expertise developing and commercializing treatments for movement
disorders and other neurological diseases,&#148; said Andre Turenne, president and chief executive officer of Voyager Therapeutics. &#147;This is a transformational collaboration for Voyager that greatly enhances our efforts towards becoming the
leading, fully-integrated gene therapy company focused on severe neurological diseases while allowing us to continue to invest in our additional pipeline programs and platform. We are tremendously excited to collaborate with the talented and
dedicated team at Neurocrine Biosciences to further advance these programs.&#148; </P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Collaboration Details and Financial Terms </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the terms of the agreement, Neurocrine Biosciences has agreed to pay Voyager $165&nbsp;million in cash including a $115&nbsp;million upfront payment and
a $50&nbsp;million equity investment at a Voyager per share price of $11.96. Voyager will also receive funding from Neurocrine Biosciences for all costs incurred on these collaboration programs as described below. In addition, Voyager may be
entitled to earn up to $1.7&nbsp;billion in development, regulatory and commercial milestone payments across the four programs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under terms of the
agreement for <FONT STYLE="white-space:nowrap">VY-AADC</FONT> for Parkinson&#146;s disease: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Neurocrine Biosciences has agreed to fund the clinical development of the Phase
<FONT STYLE="white-space:nowrap">2-3</FONT> pivotal program for <FONT STYLE="white-space:nowrap">VY-AADC.</FONT> After the data readout of the Phase 2 <FONT STYLE="white-space:nowrap">RESTORE-1</FONT> trial, Voyager has the option to either: <FONT
STYLE="white-space:nowrap">(1)&nbsp;co-commercialize</FONT> <FONT STYLE="white-space:nowrap">VY-AADC</FONT> with Neurocrine Biosciences in the U.S. under a 50/50 cost- and profit-sharing arrangement and receive milestones and royalties based on <FONT
STYLE="white-space:nowrap">ex-U.S.</FONT> sales, or (2)&nbsp;grant Neurocrine Biosciences full global commercial rights in exchange for milestone payments and royalties based on global sales. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under terms of the agreement for <FONT STYLE="white-space:nowrap">VY-FXN01</FONT> for Friedreich&#146;s ataxia: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Neurocrine Biosciences has agreed to fund the development through the Phase 1 clinical trial of <FONT
STYLE="white-space:nowrap">VY-FXN01.</FONT> After the data readout of the Phase 1 trial, Voyager has the option to either: <FONT STYLE="white-space:nowrap">(1)&nbsp;co-commercialize</FONT> <FONT STYLE="white-space:nowrap">VY-FXN01</FONT> with
Neurocrine Biosciences in the U.S. under a 60/40 cost- and profit-sharing arrangement, or (2)&nbsp;grant Neurocrine Biosciences full U.S. commercial rights in exchange for milestone payments and royalties based on U.S. sales. Sanofi Genzyme retains
an option for <FONT STYLE="white-space:nowrap">ex-U.S.</FONT> rights to <FONT STYLE="white-space:nowrap">VY-FXN01</FONT> following the data readout of the Phase 1 trial. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under terms of the agreement for the two programs to be determined: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Neurocrine Biosciences has agreed to fund the development of these programs to be determined and Voyager will
have the right to earn milestone payments and royalties based on global sales. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The effectiveness of the collaboration agreement and the
closing of the sale and issuance of Voyager common stock described above are subject to certain conditions including the expiration or termination of the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as
amended, and other customary closing conditions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Centerview Partners served as Neurocrine Biosciences&#146; financial advisor and Cooley LLP served as
Neurocrine Biosciences&#146; legal counsel for the collaboration. Wilmer Cutler Pickering Hale and Dorr LLP served as legal counsel for Voyager. </P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Conference Call Information </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Neurocrine Biosciences will host a conference call and webcast today at 8:00 a.m. EST. The live call may be accessed by dialing (866) <FONT
STYLE="white-space:nowrap">342-8588</FONT> (U.S.) or (203) <FONT STYLE="white-space:nowrap">518-9865</FONT> (International) using the conference ID: NBIX. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Voyager will host a conference call and webcast today at 8:45 a.m. EST. The live call may be accessed by dialing (877)
<FONT STYLE="white-space:nowrap">851-3834</FONT> and referencing conference ID number 3181907. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A live audio webcast of the conference calls will be
available online in the Investors section on Neurocrine Biosciences&#146; website at <U>www.neurocrine.com</U>, and from the Investors&nbsp;&amp; Media section of Voyager Therapeutics&#146; website at <U>www.voyagertherapeutics.com</U>. A replay of
the webcasts will be available on the website approximately one hour after the conclusion of each event and will be archived for approximately one month. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Voyager&#146;s <FONT STYLE="white-space:nowrap">VY-AADC</FONT> Gene Therapy for Parkinson&#146;s Disease </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">VY-AADC</FONT> is an investigational gene therapy product designed to deliver the <I>AADC</I> gene directly into neurons of
the putamen where dopamine receptors are located, bypassing the substantia nigra neurons and enabling the neurons of the putamen to produce the AADC enzyme to convert levodopa into dopamine. With this approach,
<FONT STYLE="white-space:nowrap">VY-AADC</FONT> has the potential to durably enhance the conversion of levodopa to dopamine and provide clinically meaningful improvements by restoring motor function in patients and improving symptoms following a
single administration. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The FDA granted Regenerative Medicine Advanced Therapy (RMAT) designation for <FONT STYLE="white-space:nowrap">VY-AADC</FONT> for
the treatment of Parkinson&#146;s disease in patients with motor fluctuations who are refractory to medical management. RMAT designation is an expedited program for the advancement and approval of regenerative medicine products, including gene
therapy products. RMAT designation was granted based on clinical data from the Phase 1b trial with <FONT STYLE="white-space:nowrap">VY-AADC</FONT> in patients with Parkinson&#146;s disease. During this trial,
<FONT STYLE="white-space:nowrap">one-time</FONT> administrations of <FONT STYLE="white-space:nowrap">VY-AADC</FONT> demonstrated robust and durable improvements in patients&#146; motor function along with substantial reductions in use of daily oral
levodopa and other Parkinson&#146;s disease medications. Infusions of <FONT STYLE="white-space:nowrap">VY-AADC</FONT> have been well-tolerated in this trial with no vector-related serious adverse events reported to date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Voyager recently initiated the Phase 2 <FONT STYLE="white-space:nowrap">RESTORE-1</FONT> trial in patients who have been diagnosed with Parkinson&#146;s
disease for at least four years, are not responding adequately to oral medications, and have at least three hours of OFF time during the day as measured by a validated self-reported patient diary. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For additional information regarding Voyager&#146;s <FONT STYLE="white-space:nowrap">RESTORE-1</FONT> Phase 2 clinical trial with its gene therapy <FONT
STYLE="white-space:nowrap">VY-AADC</FONT> for the treatment of Parkinson&#146;s disease, please use the following <U>link</U> or email Voyager at <U>clinicaltrials@vygr.com</U>. </P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Voyager&#146;s <FONT STYLE="white-space:nowrap">VY-FXN01</FONT> for Friedreich&#146;s Ataxia
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Friedreich&#146;s ataxia (FA) is a rare, severe, inherited neurological disease caused by mutations in the frataxin (FXN) gene leading to decreased
expression of FXN, which results in severe sensory impairment, progressive loss of the ability to walk, generalized weakness, and loss of sensation, as well as severe and potentially fatal cardiomyopathy. The typical age of onset is 10 to 12 years
with reduced life expectancy between 35 to 45 years of age due to neurological and cardiac complications. The goal of <FONT STYLE="white-space:nowrap">VY-FXN01</FONT> is to restore FXN protein levels, with a
<FONT STYLE="white-space:nowrap">one-time</FONT> treatment, to at least 50% of normal in relevant neurons and cardiac myocytes, to slow the progression of disease. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In a preclinical model of FA disease, Voyager&#146;s frataxin gene therapy vector durably improved ataxia and sensory function, and rescued the FA phenotype
based on multiple functional tests. In physiological and behavioral assays, Voyager&#146;s frataxin gene therapy vector demonstrated dose-dependent and durable responses for more than 10 months after a single administration, preventing central and
peripheral disease progression. Additional preclinical studies are underway at Voyager including steps to identify a lead clinical candidate for the treatment of FA during 2019. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Neurocrine Biosciences </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Neurocrine Biosciences, a
San Diego based biopharmaceutical company, is focused on developing treatments for neurological and endocrine related disorders. The company discovered, developed and markets INGREZZA<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>
(valbenazine) capsules, the first <FONT STYLE="white-space:nowrap">FDA-approved</FONT> product indicated for the treatment of adults with tardive dyskinesia, an involuntary movement disorder. Discovered and developed through Phase II clinical trials
by Neurocrine, ORILISSA<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> (elagolix), the first <FONT STYLE="white-space:nowrap">FDA-approved</FONT> oral medication for the management of endometriosis with associated moderate to severe pain
in over a decade, is marketed by AbbVie as part of a collaboration to develop and commercialize elagolix for women&#146;s health. Neurocrine&#146;s clinical development programs include opicapone as an adjunctive therapy to levodopa/DOPA
decarboxylase inhibitors in Parkinson&#146;s disease patients, elagolix for uterine fibroids with AbbVie, valbenazine for the treatment of Tourette syndrome, and <FONT STYLE="white-space:nowrap">NBI-74788</FONT> for the treatment of congenital
adrenal hyperplasia (CAH). For more information and the latest updates from Neurocrine Biosciences, please visit <U>www.neurocrine.com</U>. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About
Voyager Therapeutics </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Voyager Therapeutics is a clinical-stage gene therapy company focused on developing life-changing treatments for severe
neurological diseases. Voyager is committed to advancing the field of AAV gene therapy through innovation and investment in vector engineering and optimization, manufacturing and dosing and delivery techniques. Voyager&#146;s pipeline focuses on
severe neurological diseases in need of effective new therapies, including Parkinson&#146;s disease, a monogenic form of ALS called SOD1, Huntington&#146;s disease, Friedreich&#146;s ataxia, neurodegenerative diseases related to defective or excess
aggregation of tau protein in the brain including Alzheimer&#146;s disease and severe, chronic pain. Voyager has strategic collaborations with Sanofi Genzyme, AbbVie and Neurocrine Biosciences. Founded by scientific and clinical leaders in the
fields of AAV gene therapy, expressed RNA interference and neuroscience, Voyager Therapeutics is headquartered in Cambridge, Massachusetts. For more information on Voyager Therapeutics, please visit the company&#146;s website at
<U>www.voyagertherapeutics.com</U>. </P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Neurocrine Biosciences Forward-Looking Statements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition to historical facts, this press release contains forward-looking statements that involve a number of risks and uncertainties. These statements
include, but are not limited to, statements related to: statements related to the potential benefits to be derived from the Voyager Therapeutics collaboration agreement, including any statements related to Voyager&#146;s proprietary <FONT
STYLE="white-space:nowrap">CNS-focused</FONT> gene therapy platform and Neurocrine&#146;s ability to leverage such platform; Neurocrine&#146;s ability to expand its research and development pipeline, and Neurocrine&#146;s ability to develop disease
modifying and potentially curative treatments for diseases, including Parkinson&#146;s disease and Friedreich&#146;s ataxia. Among the factors and risks that could cause actual results to differ materially from those indicated in the forward-looking
statements are risks that the benefits of the agreement with Voyager may never be realized; risks that the products licensed from Voyager may not obtain regulatory approval from the FDA or such approval may be delayed or conditioned; risks that
development activities related to the products licensed from Voyager may not be completed on time or at all; risks associated with the Company&#146;s dependence on Voyager for research, development and manufacturing activities; risks that ongoing or
future clinical trials may not be successful or replicate previous clinical trial results, or may not be predictive of real-world results or of results in subsequent clinical trials; risks and uncertainties relating to competitive products and
technological changes that may limit demand for for products licensed from Voyager; risks that the products licensed from Voyager may be precluded from commercialization by the proprietary rights of third parties; and other risks that are described
in the Company&#146;s periodic reports filed with the Securities and Exchange Commission, including without limitation the Company&#146;s quarterly report on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> for the quarter ended September&nbsp;30,
2018. Neurocrine disclaims any obligation to update the statements contained in this press release after the date hereof. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Voyager Forward-Looking
Statements </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This press release contains forward-looking statements for the purposes of the safe harbor provisions under The Private Securities
Litigation Reform Act of 1995 and other federal securities laws. The use of words such as &#147;may,&#148; &#147;might,&#148; &#147;will,&#148; &#147;would,&#148; &#147;should,&#148; &#147;expect,&#148; &#147;plan,&#148; &#147;anticipate,&#148;
&#147;believe,&#148; &#147;estimate,&#148; &#147;undoubtedly,&#148; &#147;project,&#148; &#147;intend,&#148; &#147;future,&#148; &#147;potential,&#148; or &#147;continue,&#148; and other similar expressions are intended to identify forward-looking
statements. For example, all statements Voyager makes regarding the initiation, timing, progress and reporting of results of its preclinical programs and clinical trials and its research and development programs, its ability to advance its <FONT
STYLE="white-space:nowrap">AAV-based</FONT> gene therapies into, and successfully initiate, enroll and complete, clinical trials, the potential clinical utility of its product candidates, its ability to continue to develop its gene therapy platform,
its ability to develop manufacturing capability for its products and successfully transition its manufacturing process, its ability to perform under existing collaborations with, among others, Sanofi Genzyme, AbbVie and Neurocrine Biosciences and to
add new programs to its pipeline, its ability to enter into new partnerships or collaborations, the sufficiency of its cash resources and the regulatory pathway of, and the </P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
timing or likelihood of its regulatory filings and approvals for, any of its product candidates, are forward looking. All forward-looking statements are based on estimates and assumptions by
Voyager&#146;s management that, although Voyager believes to be reasonable, are inherently uncertain. All forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those that Voyager
expected. Such risks and uncertainties include, among others, the initiation and conduct of preclinical studies and clinical trials; the availability of data from clinical trials; the expectations for regulatory communications, submissions and
approvals; the continued development of the gene therapy platform; Voyager&#146;s scientific approach and general development progress; and the availability or commercial potential of Voyager&#146;s product candidates. These statements are also
subject to a number of material risks and uncertainties that are described in Voyager&#146;s most recent Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> filed with the Securities and Exchange Commission, as updated by its
subsequent filings with the Securities and Exchange Commission. Any forward-looking statement speaks only as of the date on which it was made. Voyager undertakes no obligation to publicly update or revise any forward-looking statement, whether as a
result of new information, future events or otherwise, except as required by law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">### </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Voyager Media&nbsp;&amp; Investor Relations: </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Matt
Osborne </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Vice President of Corporate Affairs, Communications and Investor Relations </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">857-259-5353</FONT></FONT> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">mosborne@vygr.com </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Neurocrine Biosciences Media&nbsp;&amp;
Investor Relations: </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Navjot Rai </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Director, Corporate
Communications </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">858-617-7623</FONT></FONT> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">IR@neurocrine.com </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g665990g21s30.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g665990g21s30.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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M@!D<L<J;HG5USC*G(H$FI*Z'T#"@ H * "@ H * "@!#0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % "%@JEF( '))[4!L1JXG4X4^61C)XS]*"4^;
MT*VE:19Z+9FULD*1%R^"Q/)^M&QG0H0P\>2&Q>H-@H * "@ H * "@!: $-
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0!4N=0B@E%O&IGN2,B&/KCU/
M91[F@RG547RK5]OZV".VDE827C!F'*Q+]Q/\3[G\J 4&]9_=T+=!J% !0 4
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M;L+\J*</A7XE:I&+J_\ &::=,XS]GMX RI[$C']:+I"M+N:7AUO'FCZX+#Q
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0 !0 4 % !0 4 % !0!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>g665990g69f98.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g665990g69f98.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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MI951;T;.@T#P?H_AQC)9P%K@C!FE.YL>@]/PK"K7G5TD==#!TL/K!:]Q^O\
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MCC*D59ZGF5,KHR=U=%ZV\ :/;:'<:2&N&AN'621B_P Q*].W%0\3-S4^QK'
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M7UILN'\V(KMMF42'/]W<0/P)YZ4 1^%X;NW\-V<-]:1VEPBD&&( *HW'' )
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M"O4LA4M('5:3IZZ;8)",%^KGU-=U*G[.-CFG+F=R]6A 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M!F7VFB;4K.]C'[R)\/[K_P#6K&=.\U)&D9VBX@NF!]>EOY1PJJL8]\<FA4[U
M.=ASVARHTZV,PH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
G* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H __9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
